Ligand Pharmaceuticals, Inc. (LGND) Misses Q2 EPS by 18c
Tweet Send to a FriendGet Alerts LGND Hot Sheet
Price: $27.57 --0%
Revenue Growth %: +108.9%
Financial Fact:
Collaborative research and development and other revenues: 4.29M
Today's EPS Names:
KID, CNET, CNTF, More
Revenue Growth %: +108.9%
Financial Fact:
Collaborative research and development and other revenues: 4.29M
Today's EPS Names:
KID, CNET, CNTF, More
Trade LGND Now!
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of ($0.20), $0.18 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $7.13 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
- ChinaNet Online Holdings (CNET) Narrows Q1 Loss on Lighter Sales
- Ligand Pharmaceuticals (LGND) Agreement with Merck KGaA Unit Terminated
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
